Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population pharmacokinetics of tenofovir in AIDS patients.
Gagnieu MC, Barkil ME, Livrozet JM, Cotte L, Miailhes P, Boibieux A, Guitton J, Tod M. Gagnieu MC, et al. Among authors: guitton j. J Clin Pharmacol. 2008 Nov;48(11):1282-8. doi: 10.1177/0091270008322908. Epub 2008 Sep 8. J Clin Pharmacol. 2008. PMID: 18779377
A template model for studying anticancer drug efflux transporter inhibitors in vitro.
Sostelly A, Payen L, Guitton J, Di Pietro A, Falson P, Honorat M, Valdameri G, Geze A, Boumendjel A, Freyer G, Tod M. Sostelly A, et al. Among authors: guitton j. Fundam Clin Pharmacol. 2013 Oct;27(5):544-56. doi: 10.1111/j.1472-8206.2012.01054.x. Epub 2012 Aug 8. Fundam Clin Pharmacol. 2013. PMID: 22882086
Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.
Bourmaud A, Henin E, Tinquaut F, Regnier V, Hamant C, Colomban O, You B, Ranchon F, Guitton J, Girard P, Freyer G, Tod M, Rioufol C, Trillet-Lenoir V, Chauvin F. Bourmaud A, et al. Among authors: guitton j. BMC Res Notes. 2015 Jul 4;8:291. doi: 10.1186/s13104-015-1231-8. BMC Res Notes. 2015. PMID: 26142140 Free PMC article.
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.
El-Madani M, Colomban O, Tod M, Maillet D, Peron J, Rodriguez-Lafrasse C, Badary OA, Valette PJ, Lefort T, Cassier P, El-Shenawy SM, El-Demerdash E, Hommel-Fontaine J, Guitton J, Gagnieu MC, Ibrahim BM, Barrois C, Freyer G, You B. El-Madani M, et al. Among authors: guitton j. Future Oncol. 2017 Apr;13(8):679-693. doi: 10.2217/fon-2016-0357. Epub 2017 Jan 12. Future Oncol. 2017. PMID: 28076966 Clinical Trial.
Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
Le Saux O, Bourmaud A, Rioufol C, Colomban O, Guitton J, Schwiertz V, Regnier V, You B, Ranchon F, Maraval-Gaget R, Girard P, Chauvin F, Freyer G, Tod M, Henin E, Trillet-Lenoir V. Le Saux O, et al. Among authors: guitton j. Cancer Chemother Pharmacol. 2018 Aug;82(2):319-327. doi: 10.1007/s00280-018-3612-x. Epub 2018 Jun 15. Cancer Chemother Pharmacol. 2018. PMID: 29948022
197 results